326 related articles for article (PubMed ID: 16398570)
1. Anagrelide: a review of its use in the management of essential thrombocythaemia.
Wagstaff AJ; Keating GM
Drugs; 2006; 66(1):111-31. PubMed ID: 16398570
[TBL] [Abstract][Full Text] [Related]
2. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
[TBL] [Abstract][Full Text] [Related]
3. [Anagrelide in the treatment of thrombocythemia essential (ET)].
Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
Gotic M; Egyed M; Gercheva L; Warzocha K; Kvasnicka HM; Achenbach H; Wu J
Cardiovasc Toxicol; 2021 Mar; 21(3):236-247. PubMed ID: 33123978
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.
Kiladjian JJ; Besses C; Griesshammer M; Gugliotta L; Harrison C; Coll R; Smith J; Birgegård G
Clin Drug Investig; 2013 Jan; 33(1):55-63. PubMed ID: 23184668
[TBL] [Abstract][Full Text] [Related]
7. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
8. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
Petrides PE
Expert Opin Pharmacother; 2004 Aug; 5(8):1781-98. PubMed ID: 15264993
[TBL] [Abstract][Full Text] [Related]
9. Long-term management of thrombocytosis in essential thrombocythaemia.
Birgegård G
Ann Hematol; 2009 Jan; 88(1):1-10. PubMed ID: 18629498
[TBL] [Abstract][Full Text] [Related]
10. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
Gugliotta L; Besses C; Griesshammer M; Harrison C; Kiladjian JJ; Coll R; Smith J; Abhyankar B; Birgegård G
Haematologica; 2014 Apr; 99(4):679-87. PubMed ID: 24334294
[TBL] [Abstract][Full Text] [Related]
12. Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with Anagrelide.
Bellucci S; Legrand C; Boval B; Drouet L; Caen J
Br J Haematol; 1999 Mar; 104(4):886-92. PubMed ID: 10192455
[TBL] [Abstract][Full Text] [Related]
13. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
[TBL] [Abstract][Full Text] [Related]
14. Anagrelide: a novel agent for the treatment of myeloproliferative disorders.
Pescatore SL; Lindley C
Expert Opin Pharmacother; 2000 Mar; 1(3):537-46. PubMed ID: 11249536
[TBL] [Abstract][Full Text] [Related]
15. Anagrelide: what was new in 2004 and 2005?
Petrides PE
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
[TBL] [Abstract][Full Text] [Related]
16. Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin.
Kellner A; Dombi P; Illes A; Demeter J; Homor L; Ercsei I; Simon Z; Karadi E; Herczeg J; Gy Korom V; Gasztonyi Z; Szerafin L; Udvardy M; Egyed M
Eur J Haematol; 2020 Oct; 105(4):408-418. PubMed ID: 32557810
[TBL] [Abstract][Full Text] [Related]
17. [Anagrelide in primary thrombocythemia].
Knutsen H; Hysing J
Tidsskr Nor Laegeforen; 2001 May; 121(12):1478-82. PubMed ID: 11449771
[TBL] [Abstract][Full Text] [Related]
18. [Primary thrombocythemia: diagnosis and therapy].
Petrides PE
Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
[TBL] [Abstract][Full Text] [Related]
19. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
Samuelson B; Chai-Adisaksopha C; Garcia D
J Thromb Thrombolysis; 2015 Nov; 40(4):474-9. PubMed ID: 25894476
[TBL] [Abstract][Full Text] [Related]
20. Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.
Griesshammer M
Expert Rev Hematol; 2009 Jun; 2(3):227-36. PubMed ID: 21082965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
